H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating on Iovance Biotherapeutics with a $32 price target after the company disclosed updates regarding the regulatory path for LN-145 in cervical cancer. With the possibility for innovaTIL-04 study to be registrational, the company is "reasonably" planning a path for a Biologics License Application submission in the second half of 2020, Pantginis tells investors in a research note. The analyst believes LN-145 "deserves the attention it is receiving." While the primary focus remains on Iovance's initial path to market with lifileucel in melanoma, LN-145 is a "potential rapid follower to commercialization," says Pantginis.